A Phase 2, Open-label Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary) ; Rucaparib (Primary)
- Indications Adenocarcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms ARIES
- Sponsors Clovis Oncology
- 11 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 25 Jun 2019 Status changed from not yet recruiting to recruiting.
- 26 Feb 2019 According to a Clovis Oncology media release, this study is expects to begin enrolling patients in the first half of 2019.